Résumé
INTRODUCTION: Thyroid hormones (TH) may affect bone metabolism and turnover, inducing a loss of bone mass among hyperthyroid and in hypothyroid patients under hormone replacement treatment. Thyroid dysfunction leads to changes in the dynamics of parathyroid hormone (PTH) and calcitonin (CT) secretion. OBJECTIVE: The objective of the study was to determine the usefulness of CT as adjuvant therapy in the prevention of bone loss during the treatment of hypothyroidism. MATERIAL AND METHODS: We studied 16 female patients with recently diagnosed primary hypothyroidism, divided into two groups: group G1 (n=8) submitted to treatment with thyroxine (L-T4), and Group 2 (n=8) that, in addition to being treated with L-T4, received a nasal CT spray. All patients were submitted to determination of TSH, free T4, bone mineral densitometry (BMD) and total bone calcium (TBC) at the time of diagnosis, after 6 to 9 months of treatment, and after 12 months of treatment. RESULTS: No statistical significant differences were detected in either group between the total BMD values obtained for the femur and lumbar spine before and after treatment. However, group G1 presented a statistical significant TBC loss after 12 months of treatment compared to initial values. In contrast, no TBC loss was observed in the group treated with LT-4 in combination with CT, a fact that may suggest that CT was responsible for the lower bone reabsorption during treatment of hypothyroidism.
Sujets)
Humains , Femelle , Ostéoporose/prévention et contrôle , Calcitonine/usage thérapeutique , Densité osseuse/effets des médicaments et des substances chimiques , Hypothyroïdie/traitement médicamenteux , Rachis/effets des médicaments et des substances chimiques , Rachis/composition chimique , Thyroxine/usage thérapeutique , Thyroxine/pharmacologie , Calcitonine/pharmacologie , Calcium/analyse , Études de suivi , Densitométrie , Association de médicaments , Fémur/effets des médicaments et des substances chimiques , Fémur/composition chimiqueRésumé
Twelve euthyroid patients who had treated with I for hyperthyroidism due to Fraves' disease and six normal controls were submitted to an EDTA infusion test. Ionized calcium and parthyroid hormone were measured in serum samples collected every 10 min during the 2-h-test. Basal values for calcium (1.22 ñ 0.03 vs 1.23 ñ 0.03 pmol/l, mean ñ SD, controls vs patients) and parathyroid hormone (3.3 ñ 0.65 vs 5.5 ñ 2.32 pmol/l_ as well as maximum response during infusion (1.01 ñ 0.04 vs 1.01 ñ 0.05 for calcium and 12.0 ñ 2.2 vs 13.1 ñ 3.7 for parathyroid hormone) were not significantly different. We conclude that I treatment for hyperthyroidism due to Graves' disease had no effect on the parathyroid gland secretory reserve of the patients studied
Sujets)
Adolescent , Adulte , Adulte d'âge moyen , Humains , Mâle , Femelle , Acide édétique , Hyperthyroïdie/radiothérapie , Radio-isotopes de l'iode/usage thérapeutique , Hormone parathyroïdienne/sang , Calcium/sang , Radio-isotopes de l'iode/effets indésirables , Glandes parathyroïdes/effets des radiationsSujets)
Adulte , Adulte d'âge moyen , Humains , Mâle , Femelle , Glycémie/analyse , Diabète de type 2/sang , Extraits de plantes/pharmacologie , Plantes médicinales , Essais cliniques comme sujet , Diabète de type 2/traitement médicamenteux , Méthode en double aveugle , Insuline/sang , Extraits de plantes/usage thérapeutique , Répartition aléatoireRésumé
Foi desenvolvido um radioimunoensaio para a medida do sulfato de deidroepiandrosterona (DHA-S) no soro. Os valores normais para diferentes grupos etarios foram determinados em 146 individuos normais. Pacientes com diferentes doencas suprarrenais e hipofisarias tambem foram estudados e apresentados os dados sobre os niveis do DHA-S